Investors and analysts are none too impressed with Pfizer's new strategies as outlined by CEO Jeffrey Kindler and other execs during an annual Wall Street update yesterday. The stock fell to within 50 cents of its 52-week low, and analysts expressed disappointment, boredom and frustration. They have been hoping--expecting--big changes from Kindler, and not unfairly, because he promised them. The one thing that might have set observers abuzz--a big acquisition--Kindler ruled out completely. Report